Insider Selling: Cytosorbents Corp Director Sells 50,000 Shares of Stock (CTSO)
Cytosorbents Corp (NASDAQ:CTSO) Director Al Kraus unloaded 50,000 shares of the company’s stock in a transaction dated Monday, June 23rd. The shares were sold at an average price of $0.23, for a total value of $11,500.00. Following the sale, the director now directly owns 1,393,631 shares of the company’s stock, valued at approximately $320,535. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of analysts have recently weighed in on CTSO shares. Analysts at Zacks reiterated an “outperform” rating on shares of Cytosorbents Corp in a research note on Friday, May 16th. They now have a $0.50 price target on the stock. Finally, analysts at Brean Capital raised their price target on shares of Cytosorbents Corp from $0.50 to $1.00 in a research note on Tuesday, April 1st. They now have a “buy” rating on the stock.
Cytosorbents Corp (NASDAQ:CTSO) traded down 3.80% on Thursday, hitting $0.2405. The stock had a trading volume of 84,680 shares. Cytosorbents Corp has a 1-year low of $0.08 and a 1-year high of $0.35. The stock has a 50-day moving average of $0.23 and a 200-day moving average of $0.21. The company’s market cap is $72.3 million.
Cytosorbents Corp (NASDAQ:CTSO) last announced its earnings results on Monday, March 31st. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.01). On average, analysts predict that Cytosorbents Corp will post $-0.02 earnings per share for the current fiscal year.
CytoSorbents Corporation is a development stage critical care focused company using blood purification to treat life-threatening illnesses.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.